Jennette JC, Falk RJ, Vacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum, 2013, 65, 1-11.
Watts RA, Mooney J, Skinner J, et al. The contras-ting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumato-logy. Rheumatology, 2012, 51, 926-931.
Mahr A, Guillevin L, Poissonnet M, et al. Preva-lences of polyarteritis nodosa, microscopic polyan-giitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000 : A capture-recapture estimate. Arthritis Rheum, 2004, 51, 92-99.
Mahr A, Katsahia S, Varet H, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis : A cluster analysis. Ann Rheum Dis, 2013, 72, 1003-1010.
Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, et al. Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remis-sion. Rheumatology, 2010, 49, 2181-2190.
Mukhtyar C, Flossmann O, Hellmich B et al. Out-comes from studies of antineutrophil cytoplasm anti-body associated vasculitis: A systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis, 2008, 67, 1004-1010.
Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Med, 2011, 90, 19-27.
Haubitz M, Schellong S, Göbel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplas-mic antibody-associated vasculitis and renal invol-vement : A prospective, randomized study. Arthritis Rheum, 1998, 41, 1835-1844.
Pagnoux C, Mahr A, Hamidou MA, et al. Azathio-prine or Methotrexate Maintenance for ANCA-Asso-ciated Vasculitis. N Engl J Med, 2008, 359, 2790-2803.
Jayne DR, Rasmussen N, Andrassy K, et al. A rando-mized trial of maintenance therapy for vasculitis asso-ciated with antineutrophil cytoplasmic autoantibodies. N Engl J Med, 2003, 349, 36-44.
de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vas-culitis: A randomized trial. Ann Intern Med, 2009, 150, 670-680.
Schönemark U, Gross WL, de Groot K. Treatment of ANCA-associated vasculitis. Nat Rev Nephrol, 2014, 10, 25-36.
Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis, 2011, 70, 488-494.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vascu-litis. N Engl J Med, 2010, 363, 221-232.
Specks U, Merkel PA, Seo P, et al. Efficacy of remis-sion-induction regimens for ANCA-associated vasculi-tis. N Engl J Med, 2013, 369, 417-427.
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med, 2010, 363, 211-220.
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associa-ted vasculitis. N Engl J Med, 2014, 371, 1771-1780.
Specks U, Fervenza FC, McDonald TJ, et al. Res-ponse of Wegeners', granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthrtitis Rheum, 2001, 44, 2836-2840.
Guerry MJ, Brogan P, Bruce IN, et al. Recomman-dations for the use of rituximab in anti-neutrophil cyto-plasm antibody-associated vasculitis. Rheumatology, 2012, 51, 634-643.
Miloslavsky EM, Specks U, Merkel PA, et al. Rituxi-mab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol, 2014, 66, 3151-3159.
Alberici F, Jayne RW. Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Nephrol Dial Transplant, 2014, 29, 1151-1159.
Pendergraft WF, Cortazar FB, Wenger J, et al. Long-term mantenance therapy using-rituximab-induced continous B-Cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol, 2014, 9, 736-744.
Charles P, Néel A, Tieulé N, et al. Rituximab for induction and maintenance treatment of ANCA-Asso-ciated vasculitides : A multicentre retrospective study on 80 patients. Rheumatology, 2014, 53, 532-539.
Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): Comparison of efficacy in granuloma-tous versus vasculitic manifestations. Ann Rheum Dis, 2012, 71, 327-333.
Guillevin L. Treatment of severe and/or refractory ANCA-associated vasculitis. Curr Rheumatol Rep, 2014, 16, 430.
Muñoz SA, Gandino IJ, Orden AO, et al. Rituxi-mab in the treatment of eosinophilic granulomatosis with polyangiitis. Reumatol Clin, 2014, [Epub ahead of print].
Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with poly-angiitis (Churg-Strauss). Ann Rheum Dis, 2014, [Epub ahead of print]
Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituxi-mab as maintenance therapy for ANCA-associated vas-culitis Rheumatology, 2014, [Epub ahead of print].
Pers JO, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum, 2007, 56, 1464-1477.
